Pressor effect of the putative M1 muscarinic receptor agonist McN-A-343 in the conscious rat

Life Sciences

Volumn 59, Issue 22, 1996, Pages 1839-1852

  Martin, John R ^a  

^a A T STILL UNIVERSITY   (United States)

Author keywords

adrenergic receptor antagonists; adrenergic receptor antagonist; M1 muscarinic receptor agonist; McN A 343; neuropeptide Y

Indexed keywords

[4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; BENEXTRAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GANGLION BLOCKING AGENT; GUANETHIDINE; LOSARTAN; LOSARTAN POTASSIUM; MUSCARINIC M1 RECEPTOR AGONIST; NEUROPEPTIDE Y; NICOTINIC RECEPTOR BLOCKING AGENT; PENTOLONIUM TARTRATE; PRAZOSIN; PROPRANOLOL; TYRAMINE; YOHIMBINE;

ADRENAL MEDULLECTOMY; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINE RELEASE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSOR RESPONSE; RAT; TACHYCARDIA;

(4-(M-CHLOROPHENYLCARBAMOYLOXY)-2-BUTYNYL)TRIMETHYLAMMONIUM CHLORIDE; ADRENAL MEDULLA; ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYSTAMINE; DRUG INTERACTIONS; GUANETHIDINE; MALE; MUSCARINIC AGONISTS; NEUROPEPTIDE Y; PRAZOSIN; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; YOHIMBINE;

ANIMALIA;

EID: 0030601670     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(96)00531-0     Document Type: Article

References (33)

1. 1. A.D. ROSZKOWSKI, J. Pharmacol. Exptl. Therap. 132 156-170 (1961).
2. 2. A. JONES, G. GOMEZ ALONSO DE LA SIERRA AND U. TRENDELENBURG, J. Pharmacol. Exptl. Therap. 139 312-320 (1963).
3. 3. M.K. KRSTIĆ, Neuropharmacol. 19 1113-1118 (1980).
4. 4. B. WILFFERT, D. DAVIDESKO, P.B.M.W.M. TIMMERMANS AND P.A. VAN ZWIETEN, J. Pharmacol. Exptl. Therap. 226 855-860 (1983).
5. 5. K.J. VAN CHARLDORP, A. DE JONGE, M.J.M.C. THOOLEN AND P.A. VAN ZWIETEN, Naunyn-Schmiedeberg's Archiv. Pharmacol. 331 301-306 (1985).
6. 6. P.R. ADAMS, D.A. BROWN AND A. CONSTANTI, J. Physiol. 332 223-262 (1982).
7. 7. Y. HASHIGUCHI, H. KOBAYASHI, T. TOSAKA AND B. LIBET, Brain Res. 242 378-382 (1982).
8. 8. R. HAMMER AND A. GIACHETTI, Life Sci. 31 2991-2998 (1982).
9. 9. H.W.G.M. BODDEKE, Eur. J. Pharmacol. 201 191-197 (1991).
10. 10. J.M. LUNDBERG, A. SARIA, A. FRANCO-CERECEDA, T. HÖKFELT, L. TERENIUS, L. AND M. GOLDSTEIN, Naunyn-Schmiedeberg's Archiv. Pharmacol. 328 331-340 (1985).
11. 11. A. FRANCO-CERECEDA, M. NAGATA, T.H. SVENSSON AND J.M. LUNDBERG, Eur. J. Pharmacol. 142 267-273 (1987).
12. 12. J.M. LUNDBERG AND K. TATEMOTO, Acta Physiol. Scand. 116 393-402 (1982).
13. 13. K.R. BORKOWSKI AND P. QUINN, Br. J. Pharmacol. 80 429-437 (1983).
14. 14. M.M. KNUEPFER AND C.A. BRANCH, J. Pharmacol. Exptl. Therap. 263 734-741 (1992).
15. 15. J.R. MARTIN, J. Cardiovasc. Pharmacol. (in press) (1996).
16. 16. A.T. CHUI, D.E. MCCALL, W.A. PRICE, JR., P.C. WONG, D.J. CARINI, J.V. DUNCIA, R.R. WEXLER, S.E. YOO, A.L. JOHNSON AND P.B.M.W.M. TIMMERMANS, Am. J. Hypertens. 4 282S-287S (1991).
17. 17. P.C. WONG, W.A. PRICE, JR., A.T. CHUI, J.V. DUNCIA, D.J. CARINI, R.R. WEXLER, A.L. JOHNSON AND P.B.M.W.M. TIMMERMANS, Am. J. Hypertens. 4 288S-298S (1991).
18. 18. A. SCHIAVONE, A. SAGRADA, R. MICHELETTI AND A. GIACHETTI, Br. J. Pharmacol. 94 566-572 (1988).
19. 19. J.R. MARTIN, J. Cardiovasc. Pharmacol. 27 891-900 (1996).
20. 20. K.H. BERECEK AND M.J. BRODY, Am. J. Physiol. 242 (Heart Circ. Physiol. 11) H593-H601 (1982).
21. 21. E.K. POTTER, Pharmacol. Therap. 37 251-273 (1988).
22. 22. J.M. LUNDBERG, A. ÄNGGÅRD, E. THEODORSSON-NORHEIM AND J. PERNOW, Neurosci. Lett. 52 175-180 (1984).
23. 23. B. EDWALL, B. GAZELIUS, S. FAZEKAS, E. THEODORSSON-NORHEIM AND J.M. LUNDBERG, Acta Physiol. Scand. 125 253-264 (1985).
24. 24. C. MELCHIORRE, M.S. YONG, B.G. BENFEY AND B. BELLEAU, J. Med. Chem. 21 1126-1132 (1978).
25. 25. M.B. DOUGHTY, S.S. CHU, D.W. MILLER, K. LI AND R.E. TESSEL, Eur. J. Pharmacol. 185 113-114 (1990).
26. 26. M.B. DOUGHTY, K. LI, L. HU, S.S. CHU AND R.E. TESSEL, Neuropeptides 23 169-180 (1992).
27. 27. W. LI, R.G. MACDONALD AND T.D. HEXUM, Eur. J. Pharmacol. 207 89-91 (1991).
28. 28. K.M. BAKER, G.W. BOOZ AND D.E. DOSTAL, Annu. Rev. Physiol. 54 227-241 (1992).
29. 29. J.D. SWALES AND N.J. SAMANI, J. Human Hypertens. 7(Suppl. 2) S3-S6 (1993).
30. 30. K. RUDOLF, W. EBERLEIN, W. ENGEL, H.A. WEILAND, K.D. WILLIM, M. ENTZEROTH, W. WIENEN, A.G. BECK-SICKLINGER AND H.N. DOODS, Eur. J. Pharmacol. 274 R11-R13 (1994).
31. 31. C. SERRADEIL-LEGAL, G. VALLETTE, P.E. ROUBY, A. PELLET, F. DURY-DONAT, G. BROUSARD, L. LESPY, E. MARTY, G. NELIAT, P. DECOINTET, J.-P. MAFFRAND AND G. LEFUR, FEBS Letters 362 192-196 (1995).
32. 32. S.S. HEDGE, D.W. BONHAUS, W. STANLEY, R.M. EGLEN, T.M. MOY, M. LOEB, S.G. SHELTY, A. DESOUZA AND J. KRSTENANSKY, J. Pharmacol. Exptl. Therap. 275 1261-1266 (1995).
33. 33. O. MUKAIYAMA, A. TAKEUCHI, T. KIMURA AND S. SATOH, J. Pharmacol. Exptl. Therap. 256 525-529 (1991).